Tools   Select Another Resource Report Type

http://www.concentris.de/

Commercial organization specialized in the management of EU-funded research projects in the HEALTH area. They carry out the non-scientific tasks of funded research projects and provide support and consultancy services for scientists and researchers at universities, in businesses and research institutes from the first project idea to the successful completion. As the project office, it is the point of reference for funded research projects. They support you with the following services: * Fund-raising and project planning * Project management * Financial management * Conference services * Dissemination and project marketing * Training organization

Proper citation: concentris research management (RRID:SCR_004100) Copy   

•   Source: SciCrunch Registry
  

http://www.diamyd.com/

A diabetes company active in the field of pharmaceutical development. The Company develops the diabetes vaccine Diamyd with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd to global Phase III trials, leading to one of Sweden''s largest biotech agreements ever. The company has secured an exclusive license for a patent application for the specific combination therapy GAD plus the endogenous substance GABA, which has demonstrated favorable results in preclinical trials. The license also encompasses rights for the therapeutic use of GABA to treat diabetes and other inflammation-related disorders.

Proper citation: Diamyd Medical (RRID:SCR_003930) Copy   

•   Source: SciCrunch Registry
  

http://www.proteomics.com/

Commercial company delivering content for personalized medicine in the areas of Biomarker Services, Biomarker Assays, Isobaric and Isotopic Reagents and Proprietary Biomarkers. A global leader in applied proteomics, they use high sensitivity proprietary technologies to detect biomarkers (differentially expressed proteins in diseases) and to develop rapid assays for testing. The biomarkers discovered in body fluids or tissues are validated, developed and commercialized as diagnostic, prognostic or therapeutic products through strategic alliances and out-licensing.

Proper citation: Proteome Sciences (RRID:SCR_004106) Copy   

•   Source: SciCrunch Registry
  

http://www.pharmo.nl/

An independent scientific research organization dedicated to the improvement of the use, quality and cost-effectiveness of pharmaceuticals. They collect, maintain and perform research on patient-centric data to derive real-life insights for tailoring of medicines. They maintain a large and high quality database network and work closely with (inter)national medical universities and European databases. Through its studies with longitudinal and real-life patient data, they contribute to risk management, outcomes research and provides solutions for decision makers in market access, health economics and health outcomes domains. Academics from Dutch universities or research institutes are granted the opportunity to perform scientific studies using the PHARMO Database Network.

Proper citation: PHARMO Institute (RRID:SCR_004105) Copy   

•   Source: SciCrunch Registry
  

http://www.wholecellkb.org/

A collection of free, open-source model organism databases designed specifically to enable comprehensive, dynamic simulations of entire cells and organisms. WholeCellKB provides comprehensive, quantitative descriptions of individual species including: * Their subcellular organization, * Their chromosome sequences, * The essentiality, location, length, direction, and homologs of each gene, * The organization and promoter of each transcription unit, * The expression and degradation rate of each RNA gene product, * The specific folding and maturation pathway of each RNA and protein species including the localization, N-terminal cleavage, signal sequence, prosthetic groups, disulfide bonds, and chaperone interactions of each protein species, * The subunit composition of each macromolecular complex, * Their genetic code, * The binding sites and footprint of every DNA-binding protein, * The structure, charge, and hydrophobicity of every metabolite, * The stoichiometry, catalysis, coenzymes, energetics, and kinetics of every chemical reaction, * The regulatory strength of each transcription factor on each promoter, * Their chemical composition, and * The composition of its typical SP-4 laboratory growth medium. WholeCellKB currently contains a single database of Mycoplasma genitalium, an extremely small gram-positive bacterium and common human pathogen. This database is the most comprehensive description of any single organism to date, and was used to develop the first whole-cell computational model. Users can download the WholeCellKB source code and content to create and customize - including the content, data model, and user interface - their own model organism database.

Proper citation: WholeCellKB (RRID:SCR_004104) Copy   

•   Source: SciCrunch Registry
  

http://www.genyo.es/en

Center for excellence research in genomic medicine, focusing on the comprehensive study and understanding of the genetic basis of human diseases in general, placing special emphasis on cancer and its genetic disorders related to inheritance. GENYO was created as a multidisciplinary research space, where different professionals from the healthcare, university and business areas interact, making it possible to generate new systems to diagnose, prevent and treat diseases based on the joint and coordinated application of first-rate knowledge in the different areas of genetics. The center is the benchmark center of the Andalusian Program for Research in Clinical Genetics and Genomic Medicine, a program which, together with those of Cell Therapy and Regenerative Medicine, and Nanomedicine have the main objective of supporting and fostering translational research in Advanced Therapies. The activities performed within these three research programs are developed in coordination with the Andalusian Initiative for Advanced Therapies (IATA), an initiative of the Andalusian Government promoted by the Regional Ministries of Health and Innovation, Science and Enterprise.

Proper citation: Centre for Genomics and Oncological Research (RRID:SCR_003920) Copy   

•   Source: SciCrunch Registry
  

http://www.polymun.at/

A private commercial company generating revenues by contract development and manufacturing biopharmaceuticals as well as creating liposomal formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. The R&D projects and technologies are open for co-development and licensing. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals (??63 Austrian Pharmaceutical Law) thus meeting the EU requirements for drug manufacturing. Its core competence is the development and manufacture of biopharmaceuticals, using both mammalian and microbial cell technology. A fine example are Polymun''s broadly neutralizing HIV-1 antibodies produced in CHO cells. Other examples are recombinant human and porcine trypsin produced in yeast. Cell culture was also the basis for the development of a live attenuated influenza vaccine produced in Vero cells which led to the further investigation in genetically modified influenza viruses used as carrier for foreign epitopes (HIV, TB). Also the innovative liposome technology was initiated in order to optimize the formulation of the pharmacologically potent enzyme SOD, produced by Polymun in E. coli. Today, Polymun can apply this drug delivery platform to all kinds of pharmaceutically active ingredients. The industrial applicability in scale and price is a common focus throughout all projects and technologies.

Proper citation: POLYMUN Scientific (RRID:SCR_003926) Copy   

•   Source: SciCrunch Registry
  

http://www.bcchf.ca/

Funding resource that raises funds to support BC Children's Hospital, Sunny Hill Health Centre for Children and the Child and Family Research Institute. The Foundation also works with Sunny Hill's Board of Directors to manage the Sunny Hill Foundation for Children. In 2013, BC Children's Hospital Foundation received donations from more than 150,000 people and had revenues of over $83 million.

Proper citation: BC Childrens Hospital Foundation (RRID:SCR_003925) Copy   

•   Source: SciCrunch Registry
  

http://www.icr.ac.uk/

Academic cancer research center, a postgrad college, and a charity in the United Kingdom that is making discoveries that defeat cancer. With their partners The Royal Marsden NHS Foundation Trust they form the largest comprehensive cancer center in Europe and perform high quality and original basic research and translational studies, with the aim of developing better treatments for the benefit of cancer patients worldwide. The ICR offers comprehensive, modern facilities for research and studentships supported by the Wellcome Trust, MRC, CRUK and EPSRC and the ICR''s own resources which are awarded on a competitive basis. The ICR offers postgraduate research degrees (MPhil, PhD and MD (Res)) and a modular postgraduate taught degree in oncology aimed at clinicians undertaking specialist training in the field of Clinical or Medical Oncology leading to a Postgraduate Certificate, Postgraduate Diploma or MSc in Oncology.

Proper citation: Institute of Cancer Research (RRID:SCR_003912) Copy   

•   Source: SciCrunch Registry
  

http://www.orion.fi/en/

A globally operating Finnish developer, manufacturer and marketer of human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. They are continuously developing new drugs and treatment methods. Pharmaceutical RD focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs.

Proper citation: Orion (RRID:SCR_003911) Copy   

•   Source: SciCrunch Registry
  

http://connecteddiscovery.com/

Commercial organization that develops pre-competitive solutions to the knowledge challenges facing drug discovery by connecting companies, leading academics and biotech specialists. It provides the bandwidth, knowledge and experience to successfully deliver pre-competitive projects through leadership, technical consulting, workflow expertise and software production. They possess over 30 years collective experience of large pharma drug discovery, computational science and knowledge management experience.

Proper citation: ConnectedDiscovery (RRID:SCR_003916) Copy   

•   Source: SciCrunch Registry
  

http://www.acttion.org/

A public-private partnership with the United States Food and Drug Administration (FDA) to identify, prioritize, sponsor, coordinate, and promote innovative activities - with a special interest in optimizing clinical trials - that will expedite the discovery and development of improved analgesic, anesthetic, and addiction medications and to more generally accelerate the development of treatments with improved efficacy and safety. This multi-year, multi-phase initiative is closely aligned with the FDA''''s Critical Path Initiative. The key objectives of ACTTION involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders - including, but not limited to, academia, the FDA and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations - with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency. ACTTION launched an initiative to develop training materials for clinical trial subjects (and staff) to be used with pain rating scales and other pain-related patient reported outcomes. Once materials have been developed and evaluated, proof-of-concept trials will be conducted to test the hypothesis that patient and staff training can improve the assay sensitivity of analgesic trials.

Proper citation: ACTTION (RRID:SCR_004003) Copy   

•   Source: SciCrunch Registry
  

http://scibite.com/

An informatics service focusing on competitor intelligence and text-mining within the life sciences. It mines a diverse array of scientific content to look for mentions of targets, indications, companies, drugs and technologies of interest to those involved in human health and drug discovery. A free newsletter service is provided to allow everyone to explore the therapeutic landscape and stay informed and a range of professional products and services are offered for those who need more in-depth analysis of the therapeutic landscape. Its text-mining engine can be configured to a variety of different use cases and performs with very high throughput. SciBite has a number of big-pharma and scientific publishers as current customers. SciBITES is free on the website but for extended functionality, including a data mining API and access to internal or commercial documents, you may wish to consider an installation of the SciBITES server software within your organization.

Proper citation: SciBite (RRID:SCR_003952) Copy   

•   Source: SciCrunch Registry
  

http://www.alz.org/research/funding/alzheimers_research_roundtable.asp

A consortium aiming to facilitate the development and implementation of new treatments for Alzheimer's disease by collectively addressing obstacles to research and development, clinical care and public health education. The Roundtable convenes twice each year for a two-day presentation and discussion of specific topics within Alzheimer's research. Topics are selected from a list proposed and voted on by members. Roundtable members explore a broad range of Alzheimer's science topics, including: * New data and technologies that may improve the diagnosis of Alzheimer's disease, especially in its earliest and mildest stages. * Neuropsychological testing, genetic factors, and biochemical and neuroimaging biomarkers that could contribute to an earlier and more accurate Alzheimer's diagnosis. * Lessons learned about clinical trial design that may help shape future clinical trials of drugs aimed at slowing or stopping the progression of Alzheimer's. * The pros and cons of various scales as outcomes measures of clinical trials. The outputs of Roundtable meetings are published as articles in the Alzheimer's Association's journal, Alzheimer's & Dementia. The Research Roundtable also sponsors Alzheimer's Association grants. The chosen project is named Research Roundtable Sponsored Grant and the principal investigator of the project is invited to give a progress report at a Roundtable meeting.

Proper citation: Alzheimers Association Research Roundtable (RRID:SCR_004007) Copy   

•   Source: SciCrunch Registry
  

http://www.hathitrust.org/

A partnership of academic and research institutions, offering a collection of millions of titles digitized from libraries around the world. Their goals are: * To build a reliable and increasingly comprehensive digital archive of library materials converted from print that is co-owned and managed by a number of academic institutions. * To dramatically improve access to these materials in ways that, first and foremost, meet the needs of the co-owning institutions. * To help preserve these important human records by creating reliable and accessible electronic representations. * To enable the digital archive to be accessible to persons who have print disabilities. * To stimulate redoubled efforts to coordinate shared storage strategies among libraries, thus reducing long-term capital and operating costs of libraries associated with the storage and care of print collections. * To create and sustain this public good in a way that mitigates the problem of free-riders. * To create a technical framework that is simultaneously responsive to members through the centralized creation of functionality and sufficiently open to the creation of tools and services not created by the central organization.

Proper citation: HathiTrust (RRID:SCR_004128) Copy   

•   Source: SciCrunch Registry
  

http://encorbio.com/

Company committed to development, characterization and manufacture of antibody and ELISA type assays for academic, biopharmaceutical and clinical research.

Proper citation: EnCor Biotechnology Inc. (RRID:SCR_003951) Copy   

•   Source: SciCrunch Registry
  

http://coherence.clir.org/

Committee to foster strategic thinking about how to more rigorously manage the transition from analog to digital in higher education to ensure the programmatic, concerted, and efficient development of large-scale projects that, if built as coherent elements of an emerging digital environment, will significantly enhance scholarly productivity and enrich teaching. The Committee will produce a blueprint for this new environment that is cost effective and sustainable by focusing on the following activities: research and analysis of key large projects and the technology requisite for their correlation; business plans necessary for a coherent, sustainable digital ecology of enormous scale in service to education and the public good; and return on investment, that is, the benefits and transformational aspects of such an undertaking.

Proper citation: Committee on Coherence at Scale for Higher Education (RRID:SCR_004127) Copy   

•   Source: SciCrunch Registry
  

http://www.wikigenes.org/

A wiki knowledge base for the life sciences that combines the collaborative and largely altruistic possibilities of wikis with explicit authorship. Authors are provided credit even while the knowledge can evolve via continual revision and traditional peer review into a rigorous scientific tool.

Proper citation: Wikigenes (RRID:SCR_004126) Copy   

•   Source: SciCrunch Registry
  

http://www.adgenetics.org/

Consortium to conduct genome-wide association studies (GWAS) to identify genes associated with an increased risk of developing late-onset Alzheimer''''s disease (LOAD). The goal of the ADGC is to identify genetic variants associated with risk for AD. It plans to do this through the following collaborative goals: # Identify genes responsible for AD susceptibility # Identify AD sub-phenotype genes rate-of-progression plaque / tangle load / distribution biomarker variability # Generate a genetic data resource for the AD research community Data generated by ADGC is available at the following website: https://www.niagads.org/content/alzheimers-disease-genetics-consortium-adgc-collection

Proper citation: Alzheimers Disease Genetics Consortium (RRID:SCR_004004) Copy   

•   Source: SciCrunch Registry
  

http://purl.bioontology.org/ontology/NIGO

Ontology that is a subset of GO directed for neurological and immunological systems. It was created by clipping those GO terms that are not associated to any gene in human, rat and mouse, and by clipping terms not found to be relevant to the neural and/or immune domains.

Proper citation: Neural-Immune Gene Ontology (RRID:SCR_004120) Copy   

•   Source: SciCrunch Registry